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ABSTRACT
Background/aims Macular pigment (MP) plays an
important role in visual function and in the protection of
the retina from oxidative damage. It is not known
whether glaucoma, a progressive neurodegenerative
disease of the optic nerve, is associated with alterations
in MP. This study was designed to investigate the
relationship, if any, between the optical density of MP
optical density (MPOD) and glaucoma.
Methods 40 subjects (23 males, 17 females) with
open angle glaucoma (mean age 69 ±11), and 54
normal controls (23 males, 31 females) without ocular
disease (mean age 66 ±11), visual acuity (VA) >6/18,
were recruited, and underwent a comprehensive eye
examination including biomicroscopy, fundoscopy,
Goldmann tonometry and visual field assessment, using
the 24-2 SITA-fast algorithm on the Humphrey visual
field analyser (II-i Series). MPOD, at 0.5° of retinal
eccentricity was determined, for all subjects, using
heterochromatic flicker photometry.
Results Median (IQR) MPOD for subjects with
glaucoma was 0.23 (0.42) compared to 0.36 (0.44) for
controls. The difference in MPOD between the glaucoma
cases and controls was statistically significant (z=
−2.158, p=0.031). There was no significant correlation
(p>0.05) between MPOD and disease severity.
Conclusions These findings suggest that MPOD is
lower in patients with glaucoma. Further investigation is
needed to determine the significance of MP in
glaucoma, its relationship to glare symptoms in
glaucoma and to assess what role therapeutic strategies
aimed at increasing MP levels could have in the
management of glaucoma.
INTRODUCTION
Glaucoma is a progressive neurodegenerative
disease of the optic nerve characterised by retinal
ganglion cell death.1 This common ocular disease is
associated with significant visual impairment and
affects approximately 60 million people world-
wide.2 Glaucoma reduces quality of life propor-
tional to the severity of visual field loss.3 Visual
symptoms are frequent. The most common visual
disabilities reported among glaucoma patients,
using a visual disability questionnaire, are poor tol-
erance of glare, present in up to 70% of subjects,
and difficulties with adaptation to different lighting
levels in 54% of subjects.4
Macular pigment (MP) plays an important role
in visual function,5–7 and in the protection of the
retina from oxidative damage.8 MP comprises the
three carotenoids: lutein, zeaxanthin and meso-
zeaxanthin, and is concentrated in photoreceptor
axons at the macula.9 It has several proposed and
established functions. The three main hypotheses
around the function of MP relate to (a) antioxidant
protection of the retina (the protective hypothesis),
(b) visual performance (the acuity, visibility and
glare hypotheses) and (c) neural function (the
neural efficiency hypothesis). In its protective role,
MP possesses optical and antioxidant properties,
functioning actively and passively, to attenuate
short wavelength light penetration and limit retinal
oxidative damage.10 The evidence in support of the
varied visual performance hypotheses suggests an
important role for MP in central visual function.7
It is, perhaps, important to note that the effects of
MP on visual performance are reliant on the com-
bined influence of all three macular carotenoids,
lutein, zeaxanthin and meso-zeaxanthin, which
appear to act synergistically to provide a more pro-
nounced and beneficial effect on vision.7 More
recently, it has also been suggested that MP also
plays a neurophysiological role, affecting temporal
vision and the neural processing of visual informa-
tion, and relating to dynamic markers of visual
health and performance.11 Lutein is also found in
the frontal and occipital cortices of the brain, cor-
relating with cerebral carotenoid concentration,
and has, therefore, been linked to cognitive
performance.12
The evidence in relation to the potential role of
MP in glare reduction is particularly relevant given
the prevalence of glare disability associated with
glaucoma. Glare can be categorised as (a) the dis-
comfort caused when the overall illumination is too
bright for the adaptation level of the eye (discom-
fort glare), and (b) the contrast reducing effect of
stray light on image quality, which causes a reduc-
tion in the visibility of a target within a visual scene
(disability glare). Often thought to be non-specific,
glare in glaucoma is associated with the severity of
visual field defects and binocular visual field loss
but is not directly linked to visual acuity (VA).12
The aetiology of glare symptoms, experienced by
glaucoma patients, is poorly understood but may
be directly related to pathological changes in neur-
onal mechanisms of the retina responsible for adap-
tion processes.13 14
Apart from glaucoma, glare is reported in other
retinal disorders including age-related macular
degeneration (AMD),6 15 and hereditary retinal
degenerations such as retinitis pigmentosa,5 both
associated with lower MP.5 16 Recent evidence sug-
gests that, for healthy subjects, glare may occur as a
direct consequence of MP loss. Low MP levels are
associated with slower photostress recovery,
increased disability glare and higher levels of visual
discomfort.17 Furthermore, oral carotenoid
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supplementation significantly increases MP and improves visual
performance under glare conditions.7 This improvement in
normal subjects has also been demonstrated in pathological dis-
orders associated with glare, including AMD.15
To date, there is no published evidence linking glaucoma and
MP. Given the proposed neurophysiological role of MP and the
link between MP and glare intolerance in other retinal disor-
ders, this study was designed to investigate if there is any rela-
tionship between MP optical density (MPOD) and glaucoma.
MATERIALS AND METHODS
Subjects
Forty subjects undergoing treatment for established glaucoma
were recruited from a glaucoma clinic at the Mater Hospital,
Dublin, Ireland. Glaucoma was defined as the presence of optic
nerve damage (cup to disc ratio >0.6 or rim notching) and
reproducible glaucomatous visual field defects. Exclusion criteria
included VA <6/18 and history or evidence of other retinal
pathology, and use of MP supplements within the past year. An
additional 54 normal controls were also recruited to participate
in this case–control study, and were excluded if ocular examin-
ation revealed any signs of ocular pathology or VA <6/18.
Typically the control group was composed of spouses and care-
givers of the glaucoma control participants. Ethical approval
was obtained from the Research Ethics Committees at Dublin
Institute of Technology and the Mater Hospital, Dublin.
Subjects provided informed consent prior to inclusion in the
study. The study adhered to the tenets of the Declaration of
Helsinki.
Demographic information, including age, gender, history of
smoking (current smoker, ex-smoker and never smoked), pres-
ence of glare (subjective glare: do you suffer from glare, yes or
no?) and years diagnosed with glaucoma, was collected in rela-
tion to each subject. One eye was selected for measurement of
MPOD. For glaucoma subjects and controls, the eye chosen was
randomly selected, except in cases where the second eye did not
meet the inclusion criteria. Subjects underwent a comprehensive
eye examination including VA, biomicroscopy, fundoscopy,
intraocular pressure assessment and visual field analysis. Current
(corrected where necessary) VA was determined using a Snellen
chart. Tonometry was measured using a Goldmann tonometer.
Visual fields were determined using the 24-2 SITA-fast algo-
rithm on the Humphrey Visual Field Analyzer, II-i Series (Carl
Zeiss Meditec, Jena, Germany). The severity of glaucomatous
visual field loss was classified using the mean deviation (MD)
value generated by the device software, into mild (MD >
−6 dB), moderate (between −6 and −12 dB) and severe (<
−12 dB) glaucoma.
Measurement of MPOD
MPOD, at 0.5° of retinal eccentricity, was determined using
Heterochromatic Flicker Photometry (HFP), measured using the
Macular Metrics Clinical Densitometer (Macular Metrics,
Rehoboth, Massachusetts, USA). The technique involves the
square-wave and counterphase presentation of two 1° lights on
a 10° blue background field, perceived as a flickering disk by the
viewer. One light is a monochromatic LEDQ10 , at 458 nm (the peak
absorbance wavelength for MP) light, whereas the other is a
monochromatic LED at 550 nm (a wavelength that MP does not
absorb). HFP was conducted by a trained examiner. All test sub-
jects were naïve to testing. The examiner explained the proced-
ure in detail, and provided a demonstration of the technique to
each subject prior to the commencement of test. A customised
HFP procedure was adopted, whereby flicker frequency was
optimised for each participant prior to measurement of MPOD.
The subject’s task was to adjust, using a press button, the radi-
ance of the 458 nm component of the test stimulus in such a
way as to eliminate the flicker from the disk. This occurs when
the 458 and 550 nm lights have the same effective luminance
for the subject. The relative energy for flicker elimination at this
retinal locus is then compared with the relative energy needed
for flicker elimination at a location in the retina that contains no
optically detectable MP (ie, 7° retinal eccentricity). The log ratio
of the difference between the central 0.5° measure and reference
7° measure yields a measure of MPOD at the test locus. As the
HFP technique is not dependent on or affected by regional var-
iations in sensitivity at the central and peripheral retinal loci
(either normal or disease induced variations), the HFP tech-
nique remains appropriate for MPOD measurement among
glaucoma subjects.
Statistical analysis
All data were entered into SPSS V.18.0. The data were tested for
normality using the Shapiro–Wilk test. Most of the data were
normally distributed and were analysed using student t tests and
Pearson correlation coefficient. Non-normally distributed data
were analysed using a Mann–Whitney U test. Median values
were used when data were non-normally distributed. A general
linear model was used to determine the effect of ocular health
status (glaucoma or control), age, gender, smoking, glaucoma
severity and years with glaucoma on the dependent variable,
MP.
Assuming a 5% level of significance, and two-tailed tests,
with 40 glaucoma cases and 54 normal controls, the study
power was 0.81 for detecting a difference of half of one SD
between groups.
RESULTS
Demographics
A total of 40 subjects, 23 males (57.5%) and 17 females
(42.5%) with glaucoma were included in this study. A further
54 controls (female: n=31; male: n=23) were also recruited.
VA ranged between 6/4 and 6/9 for subjects and controls and
was not statistically significantly different between groups. The
median length of time since diagnosis of glaucoma was 6 years,
IQR 13 years, with a range of 1–30 years. The most common
glaucoma diagnosis was primary open-angle glaucoma, n=36.
There was one case each of pseudoexfoliative syndrome, pig-
mentary dispersion glaucoma, Fuchs heterochromic iridocyclitis
and normal-tension glaucoma. Of note, 55% (n=22) of subjects
with glaucoma stated that they suffered from glare. None of the
controls reported glare. The left eye was analysed for 40%
(n=16), right eye for 60% (n=24) of glaucoma subjects. About
54% (n=29) of controls had their left eye analysed.
There was no statistically significant difference in gender
between cases of glaucoma and controls, t=−1.4, p=0.16. The
mean age of subjects with glaucoma was 69 (±11) years, com-
pared with 66 (±11) years for controls. There was no statistic-
ally significant difference in the age profiles of cases and
controls, t=1.35, p=0.18. There was no significant difference
in smoking habits between glaucoma cases and controls,
t=0.69, p=0.49.
MPOD and glaucoma
The median (IQR) MPOD for subjects with glaucoma was 0.23
(0.42), compared to 0.36 (0.44) for controls. The difference in
MPOD between the glaucoma cases and controls was statistically
significant (z=−2.16, p=0.03). A generalised linear model
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analysis confirmed a significant effect of ocular health status
(glaucoma vs control) on MPOD (p=0.04), but no effect of age,
gender, smoking, years with glaucoma, or glaucoma severity on
MPOD (p=0.2–0.97). The distribution of MPOD values, for
glaucoma cases and normal controls, is presented in figure 1.
A Pearson correlation coefficient showed a non-significant,
weak association between MPOD and MD (r=−0.1, p=0.64),
as demonstrated in figure 2. There was also a weak, non-
significant correlation between MPOD and years since diagnosis
of glaucoma (r=0.16, p=0.7).
Test–retest repeatability of the MPOD measurement, was
determined by measuring MPOD on two separate occasions, 1
week apart, for a sample of cases (n=11) and controls (n=9),
chosen by simple randomisation. The mean (±SD) MPOD
values for the initial versus the repeat test are presented in table
1, and demonstrate little change between tests.
There was a strong and statistically significant (p<0.01 for
all) test–retest Pearson correlation for the combined group
(r=0.84), normal controls (r=0.82) and glaucoma cases
(r=0.86). Paired t test analysis revealed no statistically significant
differences between repeat measures for the combined group
(p=0.59), normal controls (p=0.42) and glaucoma cases
(p=0.99). Bland Altman analysis, including limits of agreement,
revealed acceptable and equivalent levels of agreement between
repeat measures for both groups (coefficient of repeatability, cal-
culated as 1.96 times the SD of the difference between repeat
measures, was 0.25 optical density units for the glaucoma
group, which was marginally better than that observed for the
control group, at 0.27 optical density units.)
DISCUSSION
The median MPOD of the normal control group obtained here
(0.36) is in general agreement with normative data from previ-
ous studies, where MPOD typically averages around 0.35. Our
findings suggest, however, that despite considerable overlap
between groups, central MPOD is significantly lower in patients
with glaucoma when compared to those age-matched and
lifestyle-matched controls. The magnitude of the difference in
MPOD between glaucoma cases and controls (MPOD 34%
lower in glaucoma cases on average) is comparable to that
observed for other conditions, where oxidative stress is a likely
contributory factor, such as AMD, where magnitude differences
up to 53% have been reported.18 The repeatability of the test–
retest MPOD values is also similar to that observed elsewhere
among normal observers using the HFP technique,19 and pro-
vides further assurance as to the validity of the MPOD differ-
ences observed.
The relationship, if any, between glaucoma and MP is likely
complex. The absence of any association between number of
years since diagnosis or to extent of visual field loss, as cate-
gorised according to the MD index, would suggest that lower
MPOD is not simply related to glaucoma severity. It is likely,
however, that the SITA-Fast 24-2 programme used here (and
routinely in glaucoma investigation), and the MD index
reported, is not the best indicators of any functional relationship
that may exist between glaucoma and MP. Detailed analysis of
the central 10°, with particular emphasis at and close to fixation,
where MPOD typically peaks would seem more appropriate for
future investigations.
The absence of any gender, age or smoking habit differences
between the two study groups provides a substantial degree of
experimental control for those known determinants of MPOD.
It should be noted, however, that dietary carotenoid intake or
serum carotenoid levels were not quantified in the current study.
It is certainly possible that differences in dietary intake could
explain the MPOD differences observed herein. We suggest,
however, that the specific recruitment into the normal control
group of spouses and carers of glaucoma case participants likely
limits the possibility of substantial differences in dietary intake
between groups.
Although there is no published evidence linking changes in
MP to glaucoma, there is growing evidence to suggest that glau-
coma could create a suitable environment for MP loss. We
propose two possible causative mechanisms whereby MPOD
may be lower in cases of glaucoma. The first mechanism relates
to glaucoma-induced changes in both the retinal
Figure 1 Box and whisker plot showing the distribution of macular
pigment optical density (MPOD) for normal controls and for subjects
with glaucoma.
Figure 2 Scatter plot demonstrating the lack of association between
macular pigment optical density (MPOD) and the severity of glaucoma,
as measured using the mean deviation (MD) of visual fields for
glaucoma subjects.
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microcirculation and macrocirculation sufficient to disrupt MP
processing. MP is known to be entirely of dietary origin and
associated with dietary intake. Dietary supplementation with
macular carotenoids results in significant increases in serum
carotenoid and MPOD levels,20 suggesting that the retinal
microcirculation is important in MP transport to the eye.
Glaucoma is associated with a reduction in ocular blood flow
greater than expected for age which is, in part, related to
increased resistance to blood flow.21 22 Atherosclerosis, vaso-
spasm and endothelial dysfunction are all postulated to contrib-
ute to vascular regulatory dysfunction in glaucoma. These
changes may influence deposition and distribution of MP.
Supporting this, several fundal pigments are affected by glau-
coma, including oxy-haemoglobin, melanin, xanthophyll and
rhodopsin. Microcirculatory damage has been implicated in
their loss.23 Macrocirculatory changes, affecting the ophthalmic,
central retinal and posterior ciliary arteries, are also implicated
as a causative mechanism in glaucoma.24 Furthermore, a wide
variety of vascular risk factors contribute to reduced quality of
blood supply, resulting in ganglion cell death at the optic
nerve.25
The second likely causative mechanism relates the increased
oxidative stress associated with glaucoma to MP loss. There is
strong evidence that oxidative processes damage the retina,
which is susceptible to oxidative stress because of its high meta-
bolic activity and consequential oxygen consumption, high pro-
portion of polyunsaturated fatty acids, and constant exposure to
visible light.9 Retinal pigment epithelial cells are particularly sus-
ceptible to mitochondrial DNA damage under oxidative condi-
tions.26 Over recent years, there is growing evidence that
glaucoma causes significant free radical and reactive oxygen
species (ROS) production.27 In particular, toll-like receptor sig-
nalling is upregulated in glaucoma, leading to increased cytokine
production, creating a pro-inflammatory state, which may con-
tribute to retinal ganglion cell death.28 ROS, concentrated at the
trabecular membrane, are important in reducing antioxidants.29
Given the susceptibility of MP to oxidative damage, the oxida-
tive environment created by glaucoma may also cause MP loss.
Although glaucoma is traditionally associated with peripheral
visual field loss, recent technological advances have facilitated
the observation that glaucoma also causes macular ganglion cell
complex (GCC) loss, close to the fovea, even in its early
stages.30 It is plausible that the reduced macular thickness and
associated GCC loss observed in early glaucoma may be asso-
ciated with simultaneous loss of MP. Such structural changes at
the macula in glaucoma have also been associated with visual
functional losses. Despite normal VA and visual fields, colour
vision defects,31 and electrophysiological losses have also been
reported,31 further implicating glaucoma in central visual and
MP loss.
The prevalence of glare in the glaucoma group (55%), com-
pared to the normal control group (0%) is similar to that
observed in previous studies, and is also of interest.5 Given the
growing connection between MP, disability glare, and visual
discomfort,7 17 it is interesting to consider the possible connec-
tion between lower MP and glare in glaucoma. Future research
should include assessment of glare using objective measures and
questionnaires validated in patients with glaucoma such as the
Glaucoma Symptom scale. Although the benefits of carotenoid
supplementation in diseases such as AMD have not definitively
been proven, there is good evidence that supplementation
enhances MP levels.20 The potential for therapeutic interven-
tion, including for glaucoma, is also interesting, particularly
given that carotenoid supplementation in healthy subjects
reduces glare intolerance.7
In summary, this pilot study represents a preliminary investi-
gation into MPOD in glaucoma. The results, which demonstrate
lower MPOD in subjects with glaucoma, support the proposed
hypothesis that circulatory changes or oxidative stress in glau-
coma could affect MP. Further research is required to demon-
strate if MPOD is truly lower in glaucoma (with stricter control
for dietary variations in MP consumption) and if so, what are
the possible aetiologies (including any effect of treatment type
such as surgery or drug class), and whether the extent of reduc-
tion correlates reliably to loss of visual performance and espe-
cially glare.
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